News & Updates
Read the latest clinical, scientific, corporate, commercial, and event updates from TaiMed Biologics.
2023/12/14
US FDA approved the sBLA for the IV Push administration of the loading dose of Trogarzo
2023/11/17
The abstract, "A DOSE ESCALATION STUDY OF SAFETY & PK OF TMB-365 & TMB-380 IN SUPPRESSED HIV-INFECTED INDIVIDUALS", has been accepted by CROI 2024
2023/11/16
The announcement that TaiMed has initiated Phase 2 Clinical Study of Bi-monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection
2023/10/05
TaiMed submitted a revised protocol to the U.S. FDA for the core group clinical trial of the blockbuster new drug 365/380 combination
2023/09/27
The abstract, "A DOSE ESCALATION STUDY OF SAFETY & PK OF TMB-365 & TMB-380 IN SUPPRESSED HIV-INFECTED INDIVIDUALS", has been submitted to CROI
2023/09/06
Significant progress has been made in clinical trials of the blockbuster new drug 365/380 combination, and the results align with expectations.
2023/07/15
Expedite Your Biologics Development and Manufacturing with TaiMed Biologics.
2023/07/10
TaiMed is Your Reliable Biologics CDMO Service Partner
2023/03/28
TaiMed intends to terminate the exclusive sales and marketing agreement for the HIV drug Trogarzo in the Middle East and North Africa regions with Meroven Limited
2023/01/01
TaiMed has officially begun promoting the Named Patient Program (NPP) for the HIV drug Trogarzo in collaboration with WEP Clinical.